1. Home
  2. SNTI
  3. SNTI News

Latest Senti Biosciences Inc. (SNTI) News on May 25, 2024

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

GlobeNewswire

12 days ago

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Thomson Reuters StreetEvents

6 months ago

Q3 2023 Singular Genomics Systems Inc Earnings Call

Associated Press Finance

7 months ago

Cumberland: Q3 Earnings Snapshot

Share on Social Networks: